Hepatocellular carcinoma
Conditions
Interventions
Cotrol group:TACE+targeted drug
Sponsors
Beijing Ditan Hospital Affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18-80 years with hepatitis B or hepatitis C background; 2. Patients with ECoG score of 0, 1; 3. Subjects with child Pugh grade A or B in liver function; 4. Patients with liver tumor diameter <=5cm and <=3, and confirmed as HCC by 2 enhanced images or puncture pathology; 5. Patients with PVTT confirmed by biopsy (cytology or tissue); 6. Patients without tumor related treatment history (such as liver transplantation, surgical resection, radiotherapy, immunotherapy, 125I seed implantation, chemotherapy, microwave ablation, radiofrequency ablation, cryoablation, alcohol ablation, etc.).
Exclusion criteria
Exclusion criteria: 1. HCC patients with hepatic vein invasion or tumor thrombus; 2. Patients with severe liver function impairment (child Pugh score > 9, serum total bilirubin level > 3 mg / dl, refractory massive ascites, hepatic encephalopathy); 3. Patients with uncontrollable basic diseases (such as infection, cardiovascular and cerebrovascular disease, kidney disease, chronic obstructive pulmonary disease, intrahepatic bile duct expansion, etc.); 4. Patients with severe coagulation dysfunction (PLT 30 s, PTA <40%); 5. Patients with other malignant tumor or extrahepatic metastasis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OS; | — |
Secondary
| Measure | Time frame |
|---|---|
| severe adverse events; | — |
Countries
China
Contacts
Public ContactWenpeng Zhao
Beijing Ditan Hospital Affiliated to Capital Medical University
Outcome results
None listed